Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Felix B who wrote (3333)	7/15/2021 2:48:58 AM
From: CuttingEdge Bio	Respond to of 3557

Yes, that's a fair point that I should have added too. We are only talking in hindsight. At the time the deal was very beneficial, and it did a lot for Regn even if later on a few duds popped out of it. All that said, Dupixent is making the whole thing profitable anyway, so how bad is the deal really? My original point was only that the decision on treatment modality will be driven by what is needed to have a viable drug, rather than what % of the profit scale it will produce. 100% of 0 is going to be 0.